Breaking news

A new line of argument has already come to dominate the public sphere: it’ more The government has gone one step further to detect community spread of the more The government has issued an order to abolish the six allowances, including more Aarogya Setu application launched by NIC is aimed to track COVID-19 affected more SEOUL| South Korea’s unemployment rate was unchanged in April as the more Amid the outbreak of Corona pandemic in the country, Indian government has more Prime Minister Narendra Modi in his address to the nation on Tuesday indicated more Corona infection in the country is taking a macabre form. So far, more than 74 more Congress General Secretary Priyanka Gandhi Vadra has written a letter to UP more On Tuesday, Prime Minister Narendra Modi announced a package of Rs 20 lakh more

US Grants Emergency Approval to Regeneron Antibody

Regeneron antibody

United States Food and Drug Administration (FDA) has issued an emergency approval on Saturday to Regeneron Pharmaceutical’s antibody therapy that was used to treat Donald Trump.

As per the statement issued by FDA, the monoclonal antibodies, casirivimab and imdevimab, should be administered for treatment of mild to moderate COVID-19 in adults and pediatric patients with positive results of SARS-CoV-2 testing and who are at high risk of COVID-19.

“Authorising these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system,” said Stephen Hahn, commissioner of the FDA.

The agency added the antibodies are not authorised for patients who are hospitalised due to COVID-19 or require oxygen therapy due to COVID-19. A benefit of casirivimab and imdevimab treatment has not been shown in patients hospitalised due to COVID-19.

Regeneron’s antibody treatment is the second synthetic antibody treatment to receive an emergency use approval (EUA) from the FDA after a similar therapy developed by Eli Lilly was granted the status on November 9.

The human immune system naturally develops infection-fighting proteins called antibodies — but because not everyone mounts an adequate response, companies like Regeneron and Lilly have manufactured lab-made solutions.

Story Page